These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
360 related items for PubMed ID: 20979781
1. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients]. Guo FP, Yu XB, Luo L, Han Y, Qiu ZF, Zuo LY, Li YL, Yu W, Li TS. Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781 [Abstract] [Full Text] [Related]
2. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients]. Su YB, Xie J, Han Y, Qiu ZF, Li YL, Song XJ, Yu W, Li TS. Zhonghua Yi Xue Za Zhi; 2012 May 08; 92(17):1155-8. PubMed ID: 22883000 [Abstract] [Full Text] [Related]
3. Evaluation of bone mineral density in Iranian HIV/AIDS patients. Badie BM, Soori T, Kheirandish P, Izadyar S, SeyedAlinagh S, Foroughi M, Rostamian A, Mohraz M. Acta Med Iran; 2011 May 08; 49(7):460-7. PubMed ID: 21960080 [Abstract] [Full Text] [Related]
4. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J. J Clin Endocrinol Metab; 2004 Mar 08; 89(3):1200-6. PubMed ID: 15001610 [Abstract] [Full Text] [Related]
5. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. Fernández-Rivera J, García R, Lozano F, Macías J, García-García JA, Mira JA, Corzo JE, Gómez-Mateos J, Rueda A, Sánchez-Burson J, Pineda JA. HIV Clin Trials; 2003 Mar 08; 4(5):337-46. PubMed ID: 14583850 [Abstract] [Full Text] [Related]
10. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, Falchi A, Sanna D, Mura MS, Madeddu G. Q J Nucl Med Mol Imaging; 2009 Jun 08; 53(3):290-301. PubMed ID: 18596668 [Abstract] [Full Text] [Related]
12. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S. Osteoporos Int; 2018 Mar 08; 29(3):595-613. PubMed ID: 29159533 [Abstract] [Full Text] [Related]
17. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P. AIDS; 2009 Jul 17; 23(11):1367-76. PubMed ID: 19424051 [Abstract] [Full Text] [Related]
18. BMD is reduced in HIV-infected men irrespective of treatment. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC. J Bone Miner Res; 2004 Mar 17; 19(3):402-9. PubMed ID: 15040828 [Abstract] [Full Text] [Related]
19. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Schtscherbyna A, Pinheiro MF, Mendonça LM, Gouveia C, Luiz RR, Machado ES, Farias ML. Int J Infect Dis; 2012 Dec 17; 16(12):e872-8. PubMed ID: 23031418 [Abstract] [Full Text] [Related]